Cadila Pharma Looks for Acquisitions in Europe, US (India)
This article was originally published in PharmAsia News
Executive Summary
Cadila Pharmaceuticals Ltd. is one of India's leading drug manufacturers. The company has also already put down roots in America, Africa, Central and South-East Asia, Japan, Middle East and Europe. Cadila is now looking for acquisitions within regulated international markets that will help it better cultivate its brand across the globe. It is specifically targeting companies with established pharmaceutical or biotechnology products. Cadila's hope is to close a deal that will allow it the same penetration of regulated markets as it already enjoys in its production of generic drugs within unregulated markets in India and several parts of Africa. (Click here for more
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.